Sciele/Plethora initiate Phase III trials of PSD502 for Premature Ejaculation

Sciele Pharma and Plethora Solutions have initiated a Phase III Trials for PSD502 for Premature Ejaculation. PSD502 is a proprietary formulation of two marketed drugs – lidocaine and prilocaine – dispensed by a metered dose aerosol.

Columbia Laboratories report Phase II results of lidocaine in vaginal dryness

Columbia Laboratories’ vaginally-administered lidocaine has demonstrated efficacy in the treatment of vaginal dryness through dysmenorrhea. although did not meet primary endpoint

FDA accepts Zingo (lidocaine) sNDA for needle associated pain

The FDA has accepted Anesiva’s sNDA for Zingo (lidocaine intradermal injection) for the treatment of pain associated with peripheral IV insertions and blood draws in adults. Zingo was approved in 2007 for local analgesia prior to peripheral IV insertions and blood draws in children.